Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials

2013 ◽  
Vol 108 ◽  
pp. S519 ◽  
Author(s):  
William Sandborn ◽  
Jean-Frederic Colombel ◽  
Brian Feagan ◽  
Colleen Marano ◽  
Richard Strauss ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document